Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Joyce K. Hwang"'
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-11 (2021)
Abstract Less than a year since the start of the COVID-19 pandemic, ten vaccines against SARS-CoV-2 have been approved for at least limited use, with over sixty others in clinical trials. This swift achievement has generated excitement and arrives at
Externí odkaz:
https://doaj.org/article/cc73a9ce0df44954befb6b5c7f6eac20
Publikováno v:
Cancer Treatment and Research Communications, Vol 24, Iss , Pp 100183- (2020)
Since the approval of immunotherapy checkpoint inhibitors for first-line treatment of metastatic renal cell carcinoma, new and clinically relevant questions have emerged that ongoing clinical trials and trials in development will address. These quest
Externí odkaz:
https://doaj.org/article/1af54ec76d9e42c6b3879e5b4b9665b9
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:e748-e751
The discrimination of benign from malignant lymphoproliferative disorders is sometimes difficult because there can be overlap in their histological and immunophenotypic features. In such situations, molecularly based clonality testing is often used t
Autor:
Yanyan Wang, Senxin Zhang, Xinrui Yang, Joyce K. Hwang, Chuanzong Zhan, Chaoyang Lian, Chong Wang, Tuantuan Gui, Binbin Wang, Xia Xie, Pengfei Dai, Lu Zhang, Ying Tian, Huizhi Zhang, Chong Han, Yanni Cai, Qian Hao, Xiaofei Ye, Xiaojing Liu, Jiaquan Liu, Zhiwei Cao, Shaohui Huang, Jie Song, Qiang Pan-Hammarström, Yaofeng Zhao, Frederick W. Alt, Xiaoqi Zheng, Lin-Tai Da, Leng-Siew Yeap, Fei-Long Meng
Publikováno v:
Cell. 186:2193-2207.e19
Publikováno v:
Clin Cancer Res
PURPOSE: Patients with advanced renal cell carcinoma with sarcomatoid features (sRCC) have poor prognoses and suboptimal outcomes with targeted therapy. This post hoc analysis of the phase III CheckMate 214 trial analyzed the efficacy of nivolumab pl
Autor:
Rachel Tobin, Ian J. Welsby, Erin Frost, Bhavik N. Patel, Thomas L. Ortel, Chester Kao, Molly M Daughety, Matthew Fuller, Joyce K. Hwang, Andrew Morgan
Publikováno v:
Thrombosis Research
Highlights • COVID-19 patients are at increased risk of thromboembolic complications. • Escalated-dose thromboprophylaxis may help reduce the rate of thromboembolic events. • The bleeding risk is highest for patients treated with therapeutic an
Autor:
Tian Zhang, Daniel J. George, Joyce K. Hwang, Riddhishkumar Shah, April K.S. Salama, Kathleen Ashcraft, Hannah Dzimitrowicz
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundPatients with cancer are at high risk for severe COVID-19 disease and mortality1; however, patients on active cancer treatment, including immune checkpoint inhibitors (ICI), were excluded from COVID19 vaccine trials.2 3 Thus, safety and eff
Autor:
Ian J. Welsby, Chester Kao, Molly M Daughety, Joyce K. Hwang, Thomas L. Ortel, Andrew Morgan, Erin Frost, Bhavik N. Patel
Publikováno v:
Blood
Introduction: Early studies identified a prothrombotic state associated with novel coronavirus disease 2019 (COVID-19) as well as a survival benefit observed with heparin use in severely ill COVID-19 patients. There is a need to clarify the incidence
Autor:
John R. Mascola, Thomas B. Kepler, Robin M. Meyers, Peter D. Kwong, M. Gordon Joyce, Joyce K. Hwang, Leng-Siew Yeap, Chong Wang, Zhou Du, Mattia Bonsignori, Donna Neuberg, Barton F. Haynes, Frederick W. Alt
Publikováno v:
Proceedings of the National Academy of Sciences. 114:8614-8619
Variable regions of Ig chains provide the antigen recognition portion of B-cell receptors and derivative antibodies. Ig heavy-chain variable region exons are assembled developmentally from V, D, J gene segments. Each variable region contains three an
Publikováno v:
Cancer Treatment and Research Communications, Vol 24, Iss, Pp 100183-(2020)
Since the approval of immunotherapy checkpoint inhibitors for first-line treatment of metastatic renal cell carcinoma, new and clinically relevant questions have emerged that ongoing clinical trials and trials in development will address. These quest